

What is claimed is

1. Human thrombopoietin derivative which derived from human thrombopoietin (hTPO) described by SEQ ID NO: 30; which has at least one additional N-linked glycosylation site; and which is selected from the group comprising:

5 [Asn¹⁰⁸] hTPO;

10 [Asn¹¹⁷] hTPO;

15 [Asn¹⁴⁷] hTPO;

20 [Asn¹⁵³] hTPO;

25 [Asn¹⁶⁴] hTPO;

Sub
B1

[Asn¹⁹³] hTPO;

[Asn¹¹⁷, Asn¹⁴⁷] hTPO;

[Asn¹¹⁷, Asn¹⁶⁴] hTPO;

[Asn¹⁰⁸, Asn¹⁴⁷] hTPO;

[Asn¹⁰⁸, Asn¹⁶⁴] hTPO;

[Asn¹⁴⁷, Asn¹⁶⁴] hTPO;

[Asn¹¹⁷, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;

[Asn¹⁰⁸, Asn¹⁴⁷, Asn¹⁶⁴] hTPO;

[Asn¹⁰⁸, Asn¹¹⁷, Asn¹⁶⁴] hTPO;

[Asn¹⁵⁷, Asn¹⁶⁴] hTPO;

[Asn¹⁶², Ser¹⁶⁴] hTPO;

[Asn¹⁶², Thr¹⁶⁴] hTPO;

[Asn¹⁵³, Ser¹⁵⁵, Asn¹⁶⁴] hTPO;

[Asn¹⁵³, Thr¹⁵⁵, Asn¹⁶⁴] hTPO;

[Asn¹⁵⁹, Ser¹⁶¹, Asn¹⁶⁴] hTPO;
[Asn¹⁵⁹, Thr¹⁶¹, Asn¹⁶⁴] hTPO;
[Asn¹⁶⁶, Ser¹⁶⁸] hTPO;
[Asn¹⁶⁶, Thr¹⁶⁸] hTPO; and
5 [Asn¹⁶⁴, Asn¹⁶⁸] hTPO.

2. The human thrombopoietin derivative of claim 1 which is [Asn¹⁶⁴] hTPO, [Asn¹⁹³] hTPO, [Asn¹⁰⁸, Asn¹¹⁷, Asn¹⁶⁴] hTPO, or [Asn¹⁵⁷, Asn¹⁶⁴] hTPO.

10 3. Recombinant gene encoding human thrombopoietin derivative of claim 1.

15 4. Recombinant gene encoding human thrombopoietin derivative of claim 2.

5. Eukaryotic expression vector containing the recombinant gene of claim 3.

20 6. The eukaryotic expression vector of claim 5 which is p40433, p40434, p40449, p40458, pD40433, pD40434, pD40449, or pD40458.

25 7. Mammalian cell line CHO K-1/p40433 (Accession NO: KCTC 0495BP) transfected with the expression vector p40433 of claim 6.

8. Mammalian cell line CHO dhfr-/pD40434 (Accession
NO: KCTC 0630BP) transfected with the expression
vector pD40434 of claim 6.

5 9. Mammalian cell line CHO dhfr-/pD40449 (Accession
NO: KCTC 0631BP) transfected with the expression
vector pD40449 of claim 6.

10 10. Mammalian cell line CHO dhfr-/pD40458 (Accession
NO: KCTC 0632BP) transfected with the expression
vector pD40458 of claim 6.

15 11. Process of preparing the human thrombopoietin
derivative of claim 1 wherein a mammalian cell line
containing the recombinant gene of claim 3 is used
to obtain the human thrombopoietin derivative of
claim 1.

SNB
AH

20 12. Pharmaceutical composition containing the human
thrombopoietin derivative of claim 1 which is used
for the treatment of thrombocytopenia.